Granules India targets $100 million peptide CDMO revenue within five years
The ₹2,000 crore organic capex plan leans on Senn Chemicals to move the generics maker into complex peptide manufacturing.
The wire
- 01Granules India outlined a ₹2,000 crore organic capital expenditure program over three to four years, with its peptide CDMO arm targeting a $100 million revenue run rate in five years.
- 02Oral peptide programs are driving large API volume demand, and another contract manufacturer scaling up affects supply options for peptide developers.
- 03The targets are company guidance, not booked revenue; the report also notes AI-assisted drafting and advises independent verification.
From the source
Read at sahi.comGranules India Targets ₹2,000 Crore Organic CAPEX And $100 Million Peptide Revenue
Granules India is pivoting from legacy bulk generics to high-value formulations, funded by a ₹2,000 crore organic CAPEX. Key drivers include its peptide CDMO arm targeting a $100 million run rate in 5 years, and a key First-to-File generic challenge for Ruxolitinib Extended-Release tablets, which could grant 180 days of US exclusivity.
